AstraZeneca drew some retail investor attention early Monday after the pharma major reported that its cancer therapy Enhertu, developed with Daiichi Sankyo, achieved the highest pathologic complete ...

Epcoritamab plus chemoimmunotherapy achieved an 87% overall response rate in relapsed/refractory DLBCL patients, with 65% achieving complete response. The regimen offers a potential bridge to ASCT or ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Detalimogene coraplasmid shows a promising CR rate for high-risk, BCG-unresponsive non-muscle invasive bladder cancer, with 63% achieving CR at any time. The treatment is well tolerated, with 42% ...

Patients diagnosed with recurrent or progressive extensive-stage small cell lung cancer (ES-SCLC) may benefit from treatment with ifinatamab deruxtecan (I-DXd), a B7-H3–directed antibody–drug ...

With all the excitement over the new immune-checkpoint inhibitor drugs in melanoma, many of which are not yet available, it's easy to overlook another immunotherapy — tumor infiltrating lymphocytes ...

Epcoritamab combined with R-mini-CHOP or R-CHOP shows high ORR and CR rates in newly diagnosed DLBCL patients, including high-risk and older populations. The trial achieved significant MRD negativity, ...

COPENHAGEN, Denmark, October 17, 2025 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new two-year ...

Axitinib combined with octreotide long-acting release (LAR) significantly improved progression-free survival (PFS) per blinded independent central review (BICR) and objective response rate in patients ...

SAN CARLOS, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel ...